Get the Stockscreener App
0.00
100.00%
-0.84
Salarius Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$0.84
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$4.92M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
0.00
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$34.65
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.00 | 4.92M | 4.70M | -4.99M | -5.29M | -6.42 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
165.01 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Ladenburg Thalmann | Buy |
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Aug Swings: What are the future prospects of Salarius Pharmaceuticals IncInsider Selling & Weekly Breakout Watchlists - baoquankhu1.vn
Trade Recap: Is Salarius Pharmaceuticals Inc forming a bullish divergence2026 Support & Resistance & Stepwise Swing Trade Plans - baoquankhu1.vn
Aug Summary: Can Salarius Pharmaceuticals Inc continue delivering strong returnsWeekly Trend Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
US Market Recap: Is Salarius Pharmaceuticals Inc subject to activist investor interest2026 Technicals & Reliable Trade Execution Plans - baoquankhu1.vn
Short Squeeze: Can Salarius Pharmaceuticals Inc continue delivering strong returnsPortfolio Performance Report & Accurate Trade Setup Notifications - baoquankhu1.vn
If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan
Breakout Move: Will Salarius Pharmaceuticals Inc outperform tech stocksTrade Risk Summary & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Gainers Report: Will Salarius Pharmaceuticals Inc stock hit new highs in YEARPrice Action & AI Powered Market Trend Analysis - baoquankhu1.vn
Momentum Shift: Can Salarius Pharmaceuticals Inc outperform under higher oil prices2026 Highlights & Long-Term Capital Growth Strategies - baoquankhu1.vn
Salarius Pharmaceuticals appeals Nasdaq delisting after bid deficiency - MSN
Panic Selling: Is Salarius Pharmaceuticals Inc benefiting from interest rate changesM&A Rumor & Growth Focused Investment Plans - baoquankhu1.vn
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
Analyst Upgrade: Can Salarius Pharmaceuticals Inc. outperform under higher oil prices2026 Movers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Aug Shorts: Is Salarius Pharmaceuticals Inc. subject to activist investor interestJuly 2025 Gainers & AI Driven Price Predictions - baoquankhu1.vn
Buy Signal: Is Salarius Pharmaceuticals Inc benefiting from interest rate changesMarket Sentiment Summary & Technical Pattern Based Signals - baoquankhu1.vn
Risk Recap: Is Salarius Pharmaceuticals Inc subject to activist investor interestWeekly Trend Report & AI Driven Price Predictions - baoquankhu1.vn
Will Salarius Pharmaceuticals Inc outperform tech stocks2025 Risk Factors & Verified Short-Term Trading Plans - baoquankhu1.vn
SLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aug Momentum: Can Salarius Pharmaceuticals Inc continue delivering strong returns2025 Geopolitical Influence & High Return Trade Opportunity Guides - baoquankhu1.vn
Aug Gainers: Will Salarius Pharmaceuticals Inc be affected by tariffsDay Trade & High Accuracy Trade Alerts - baoquankhu1.vn
Decoy Therapeutics (NASDAQ: DCOY) wins approval for equity plan and reverse split - Stock Titan
SLRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Levels Update: Can Salarius Pharmaceuticals Inc outperform under higher oil pricesWeekly Earnings Recap & AI Based Trade Execution Alerts - baoquankhu1.vn
Can Salarius Pharmaceuticals Inc weather a recessionSell Signal & Growth Oriented Trading Recommendations - baoquankhu1.vn
Short Covering: Can Salarius Pharmaceuticals Inc benefit from deglobalizationCEO Change & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Is Salarius Pharmaceuticals Inc. benefiting from interest rate changesJuly 2025 Outlook & Verified Chart Pattern Trade Signals - mfd.ru
CVI and Heights disclose 9.9% Decoy Therapeutics (DCOY) warrant stake - Stock Titan
Aug PreEarnings: Is Salarius Pharmaceuticals Inc. benefiting from interest rate changesJuly 2025 Final Week & Consistent Profit Trade Alerts - mfd.ru
What are the future prospects of Salarius Pharmaceuticals Inc.Trend Reversal & Consistent Return Investment Signals - mfd.ru
Aug Breakouts: Is Salarius Pharmaceuticals Inc forming a bullish divergenceWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Value Recap: Can Salarius Pharmaceuticals Inc benefit from deglobalizationMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Signal Recap: What are the future prospects of Salarius Pharmaceuticals Inc2025 Key Highlights & Daily Profit Maximizing Tips - baoquankhu1.vn
Trend Review: Is AMRN a cyclical or defensive stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Trend Report: What are the future prospects of Salarius Pharmaceuticals Inc2025 Trading Volume Trends & Breakout Confirmation Alerts - baoquankhu1.vn
Aug Volume: What analysts say about Salarius Pharmaceuticals Inc stock - baoquankhu1.vn
Travel Stocks: Can Salarius Pharmaceuticals Inc weather a recession2025 Market Outlook & AI Driven Stock Reports - baoquankhu1.vn
Aug Analyst Calls: Can Salarius Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Patterns & High Conviction Investment Ideas - baoquankhu1.vn
Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Expands By 20.9% - Defense World
What analysts say about Salarius Pharmaceuticals Inc. stockDividend Stock Watch & Low Risk Investment Plans - Bollywood Helpline
Momentum Shift: Is Salarius Pharmaceuticals Inc benefiting from interest rate changesWeekly Investment Summary & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Meme Stocks: Can Salarius Pharmaceuticals Inc benefit from deglobalizationJuly 2025 Pullbacks & Safe Entry Zone Tips - baoquankhu1.vn
DCOY Stock Price, News & Analysis - Stock Titan
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - marketscreener.com
US Stocks Recap: Will Salarius Pharmaceuticals Inc. stock benefit from infrastructure spendingMarket Activity Report & Daily Risk Controlled Trade Plans - Bộ Nội Vụ
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - Finviz
Decoy Therapeutics reaches global access commitment agreement to focus on development of a globally accessible, scalable peptide-conjugate manufacturing platform - marketscreener.com
Outbreak-ready antiviral network for low- and middle-income countries - Stock Titan
Salarius Pharmaceuticals, Inc. (DCOY) Stock Live Price, Chart & News - CoinCodex
Forecast Cut: Can Salarius Pharmaceuticals Inc weather a recessionProduct Launch & Safe Entry Zone Identification - baoquankhu1.vn
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Salarius Pharmaceuticals Inc Stock (SLRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
1.52%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):